BioSpace News Archive

Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it has submitted a response to the European Medicines Agency’s (EMA) second Day 180 list of outstanding issues for ATIR101

Centauri Therapeutics (“Centauri”) is an immunotherapy company active in oncology and infectious diseases.

On May 23, 2019, the US-based chemical company BOC Sciences announces to upgrade its ADCs product line for cancer research as a targeted drug therapy. In addition to providing top quality ADCs that are GMP manufactured, BOC Sciences also provides custom synthesis service to develop antibody-drug conjugates based on individual needs for all phases of drug development.

AdAlta Limited (ASX: 1AD) is pleased to announce the placement of up to 33,333,333 fully paid ordinary shares in the Company to sophisticated and institutional investors at a price of $0.15 per share to raise $5 million (before costs) (Placement).

Santhera Pharmaceuticals (SIX: SANN) announces that it has entered into an exclusive license agreement with Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), under which Chiesi Group will in-license Raxone® for the treatment of LHON for a total consideration of up to CHF 105 million

On May 23, 2019, the global leading peptide expert Creative Peptides announced to upgrade its amino acids for researchers involved in relevant field, extending the product line into different categories like amino acids & derivatives, glycosylated amino acids, protected amino acids, stable isotope labeled amino acids and other amino acids.

BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), today announced positive top line data from its Phase 1 pharmacokinetic (PK) (bioavailability) and safety study of BXCL501, a proprietary sublingual thin-film formulation of dexmedetomidine (Dex), for the acute treatment of agitation across multiple neuropsychiatric indications.

Australian researchers have used a unique combination of cutting-edge technologies to discover a biochemical mechanism fundamental to life.

Medigene AG announced that it entered into a Clinical Trial Agreement with the Leiden University Medical Center, the Netherlands, to conduct a Phase I clinical trial with Medigene’s T cell receptor modified T cell therapy MDG1021 targeting the HA-1 antigen.

Late-Breaking Clinical Trial Results and Updated Global SYMPLICITY Registry Data Demonstrate Long-Term Results of RDN for Uncontrolled Hypertension